Edesa Biotech (EDSA) CFO receives 64,609 restricted share units under 2019 plan

Rhea-AI Filing Summary

Weiler Peter J. reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. reported that its Chief Financial Officer, Peter J. Weiler, received an equity grant in the form of restricted share units. He was awarded 64,609 Common Shares at a price of $0.00 per share as a compensation-related grant, not an open‑market purchase.

The grant was issued under the company’s 2019 Equity Incentive Compensation Plan and will vest monthly in equal portions over 36 months starting on the grant date. Following this award, Weiler directly holds 129,609 Common Shares, aligning a larger portion of his pay with the company’s future share performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Weiler Peter J.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	64,609	$0.00	--

Holdings After Transaction: Common Shares — 129,609 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 64,609 Common Shares Grant price: $0.00 per share Post‑grant holdings: 129,609 Common Shares +1 more

4 metrics

RSU grant size 64,609 Common Shares Restricted share units granted to CFO on May 27, 2026

Grant price $0.00 per share Price for restricted share unit grant to CFO

Post‑grant holdings 129,609 Common Shares Total Common Shares held directly by CFO after transaction

Vesting period 36 months RSUs vest monthly in equal proportions from grant date

Key Terms

restricted share units, 2019 Equity Incentive Compensation Plan, vest monthly, Grant, award, or other acquisition

4 terms

restricted share units financial

"Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Equity Incentive Compensation Plan financial

"issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly"

vest monthly financial

"which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weiler Peter J.

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM L3R 5H6

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	05/27/2026		A		64,609(1)	A	$0(1)	129,609	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date.

	/s/ Peter J. Weiler	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Edesa Biotech (EDSA) report for its CFO?

Edesa Biotech reported that CFO Peter J. Weiler received a grant of 64,609 Common Shares as restricted share units. The award is compensation-related, carries a $0.00 grant price, and was made under the company’s 2019 Equity Incentive Compensation Plan.

How many Edesa Biotech (EDSA) shares does the CFO hold after this Form 4?

After the reported transaction, CFO Peter J. Weiler holds 129,609 Common Shares directly. This reflects the addition of 64,609 restricted share units granted at a $0.00 price, which will vest over time under the 2019 Equity Incentive Compensation Plan.

Is the Edesa Biotech (EDSA) CFO’s Form 4 transaction a market purchase or a grant?

The transaction is a grant, not a market purchase. CFO Peter J. Weiler received 64,609 Common Shares as restricted share units at a $0.00 price under Edesa Biotech’s 2019 Equity Incentive Compensation Plan, classified as a grant, award, or other acquisition.

How do the Edesa Biotech (EDSA) CFO’s restricted share units vest?

The restricted share units granted to the Edesa Biotech CFO vest monthly in equal proportions over 36 months. Vesting begins on the grant date, meaning a portion of the 64,609 units becomes unrestricted each month during this three‑year period.

What plan governed the Edesa Biotech (EDSA) CFO’s recent equity grant?

The grant was issued under Edesa Biotech’s 2019 Equity Incentive Compensation Plan. Under this plan, CFO Peter J. Weiler received 64,609 restricted share units that vest monthly over 36 months, aligning his compensation more closely with Edesa Biotech’s share performance.